Skip to content
  • Sunday, 26 July 2026
  • 1:45 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Moderna Bets on mRNA’s Second Act with Cancer, Autoimmune Programs, and AI Research Platform
Laboratory Automation & Robotics

Moderna Bets on mRNA’s Second Act with Cancer, Autoimmune Programs, and AI Research Platform

Lana Keisha Jul 22, 2026 0

At its recent annual Science Day, Moderna signaled a profound strategic shift, moving beyond its foundational infectious disease vaccine and…

Read More
Laboratory Automation & Robotics

Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform

Lana Keisha Jul 15, 2026 0

At its recent annual Science Day, biotechnology giant Moderna signaled a profound strategic expansion beyond its highly successful infectious disease…

Read More
Laboratory Automation & Robotics

Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform

Lana Keisha Jul 7, 2026 0

Moderna, the biotechnology firm that gained global prominence for its mRNA-based COVID-19 vaccine, is embarking on a significant strategic pivot,…

Read More
Laboratory Automation & Robotics

BioNTech’s Post-Pandemic Pivot: From €19 Billion Vaccine Bonanza to Oncology’s €16.8 Billion Bet Amidst Job Cuts and Shifting mRNA Landscape

Lana Keisha May 28, 2026 0

The German biotechnology firm BioNTech, a name synonymous with the rapid development of the world’s first widely authorized mRNA COVID-19…

Read More
Laboratory Automation & Robotics

FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine

Lana Keisha Apr 18, 2026 0

The U.S. Food and Drug Administration (FDA) has officially reversed its earlier decision regarding Moderna’s investigational mRNA influenza vaccine (mRNA-1010),…

Read More
Laboratory Automation & Robotics

FDA Rejects Moderna’s mRNA Flu Vaccine Application, Citing Comparator Study Flaws Amidst Broader Policy Shifts

Lana Keisha Apr 6, 2026 0

Moderna, a leading biotechnology company, announced on Tuesday that the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation…

Read More
Laboratory Automation & Robotics

FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine

Lana Keisha Apr 4, 2026 0

The U.S. Food and Drug Administration (FDA) has officially reversed its earlier stance on Moderna’s innovative mRNA influenza vaccine candidate,…

Read More
Laboratory Automation & Robotics

FDA Refuses to Review Moderna’s mRNA Flu Vaccine Application, Citing Comparator Study Design

Lana Keisha Mar 28, 2026 0

Washington D.C. – Moderna, a leading biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has issued…

Read More
Laboratory Automation & Robotics

FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine

Lana Keisha Mar 27, 2026 0

In a significant development for vaccine innovation and public health, the U.S. Food and Drug Administration (FDA) has reversed its…

Read More
Biotech & Genetic Research

The modification of lipid nanoparticles with aromatic rings and disulfide bonds enhances mRNA vaccine delivery.

Jia Lissa Mar 25, 2026 0

Researchers at the University of Pennsylvania (PA, USA) have achieved a significant breakthrough in mRNA vaccine technology, modifying lipid nanoparticles…

Read More

Posts pagination

1 2
Getting Started with smolagents: Build Your First Code Agent in 15 MinutesStudy: Toxic Exposure in Pregnancy May Drive Disease Risk Across GenerationsRIKEN Physicists Propose Breakthrough Method for Robust One-Way Quantum Synchronization of PhononsBuild an AI-Powered Learning Management System That Actually Trains People
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ